A data-heavy pharma case study on how Pfizer, BMS, Lilly and other global drugmakers are licensing Chinese biotech assets as patent cliffs, R&D cost pressure and oncology competition reshape Big Pharma strategy.
For years, China was seen by many global pharma companies as a manufacturing base, a commercial expansion market, and a place for lower-cost clinical development. That view is now outdated. China is becoming one of the most important innovation suppliers to global pharma.
Pfizer’s USD 10.5 Billion Bet on Innovent
The latest signal came when Pfizer and Innovent Biologics announced a global strategic collaboration to develop 12 early-stage and de novo cancer medicine programs. Reuters reported the deal value at up to USD 10.5 billion, including USD 650 million upfront. The agreement includes eight Innovent-originated early-stage programs and four Pfizer-proposed discovery programs.
This is the important part: Pfizer is not buying one late-stage product. It is buying access to a pipeline engine. That tells the market something deeper. Global pharma is no longer looking at China only for single assets. It is looking at China as an R&D infrastructure.
The Big Number: USD 137.7 Billion in China Out-Licensing
Reuters reported that 38 China out-licensing deals had already been announced by mid-February 2026, after 186 such deals in 2025. The market message is clear: China-origin pharma innovation is becoming more expensive because global demand for it is rising.
BMS-Hengrui: The USD 15.2 Billion Signal
Bristol Myers Squibb and Hengrui Pharma announced strategic agreements across oncology, hematology and immunology. The potential total value is up to approximately USD 15.2 billion, including options and milestone payments. The collaboration covers 13 early-stage programs.
This deal is strategically different from a simple licensing transaction. It is two companies exchanging capabilities: BMS brings global development and commercialization muscle; Hengrui brings discovery speed and China-origin pipeline depth. China is no longer just a seller of assets. It is becoming a strategic R&D partner.
Lilly-Haisco: China Deal Flow Moves Beyond One Company
Eli Lilly signed a collaboration and licensing agreement with a unit of Haisco Pharmaceutical Group, with potential milestone-based payments totaling up to about USD 3 billion. The collaboration covers up to five innovative target programs across multiple therapeutic areas — pain management, oncology, respiratory, autoimmune, metabolic and CNS disorders.
This matters because the China biotech story is not only oncology. It is spreading across metabolic disease, immunology, respiratory disease, pain and CNS — high-value therapeutic areas where global demand is strong.
The Why: Patent Cliff Pressure Is Forcing Big Pharma to Move Faster
Evaluate reported that the global pharmaceutical industry is on track to surpass USD 1.75 trillion in prescription drug sales by the end of the decade, but also highlighted a patent cliff with more than USD 300 billion in sales at risk by 2030. Chinese-origin assets are expected to make up nearly 40% of global licensing deals in 2025.
Internal R&D alone is too slow, too expensive and too risky. If a Western pharma company can license a promising China-origin oncology or metabolic asset earlier, cheaper, and faster than building everything internally, it can reduce pipeline risk and buy time before patent losses hit revenue. The real deal is time. Big Pharma is buying time before the patent cliff.
The ADC Factor: China’s “Guided Missile” Advantage
One of the strongest areas in this boom is antibody-drug conjugates, or ADCs. Reuters reported that China leads in specialised molecule types and accounted for nearly 90% of global ADC licensing activity. ADCs are cancer medicines designed like guided missiles: an antibody targets cancer cells and carries a toxic payload more directly toward the tumor.
ADCs and multispecific antibodies are high-complexity biologic innovation areas. If Chinese companies are supplying a large share of global ADC licensing opportunities, then China is no longer sitting at the low-value end of pharma. It is entering the premium end. That is a major shift.
The Business Model Has Changed
Many Chinese biotechs are now creating broad pipelines, licensing multiple assets, retaining Greater China rights, and selling global rights outside China to multinationals. This creates a hybrid model: China keeps domestic/regional upside while Big Pharma gets global commercialization rights.
The Pfizer-Innovent structure shows sophisticated deal architecture — some programs co-developed and co-commercialized with shared profits in the US and Europe, some granting Pfizer exclusive rights outside Greater China, and some globally licensed exclusively to Pfizer. Chinese companies are no longer behaving like desperate sellers. They are designing deals to keep value, share risk, and access global infrastructure.
The Geopolitical Risk Is Real
Big Pharma wants China’s pipeline. But the US political system is becoming more suspicious of biotech dependence on China. Growing national-security concerns around US pharma reliance on Chinese biotech firms create a strange contradiction: commercially, China biotech is attractive; politically, China biotech is sensitive.
Every major China licensing deal now carries two valuations: scientific value and geopolitical risk. CEOs cannot treat China licensing as normal business development anymore. It is business development plus political-risk management.
The India Lesson: Generics Are Not Enough
India’s pharmaceutical exports reached USD 30.47 billion in FY 2024–25, growing 9.4%. The Indian pharma sector is valued at around USD 60 billion and is projected to reach USD 130 billion by 2030. That is a strong foundation. But China’s biotech licensing boom sends a warning: volume leadership is not the same as innovation leadership.
India remains powerful in generics, formulations, APIs and cost-efficient manufacturing. But the highest-value deals are increasingly going toward innovative biologics, oncology assets, ADCs, multispecific antibodies and novel targets. The next opportunity for Indian pharma is not only to export more tablets. It is to build license-worthy innovation.
The Investor & CEO Lesson
For investors, this story changes how pharma pipelines should be evaluated. A company’s R&D strength is no longer limited to what it discovered internally. It also depends on how intelligently it licenses external innovation. Investors should now ask how much of the future pipeline comes from external deals, how many assets are China-origin, who owns US/Europe rights, and whether milestone payments are realistic.
- How much of our future pipeline will come from external China-origin deals?
- Are these assets early-stage discovery or clinically validated?
- Who owns US and Europe rights versus Greater China rights?
- What is our geopolitical exposure review process for these deals?
- Can we manufacture and commercialize these assets globally at scale?
- Are milestone payments realistic or headline-heavy?
- Can these deals meaningfully replace revenue lost to patent cliffs?
The Next Phase
China-origin assets will become more expensive as demand rises. Average upfront payments have already doubled in 2026 compared with 2025. More Western companies will compete for the same high-quality assets. More Chinese biotechs will demand better economics. More policymakers will examine cross-border biotech dependence.
The early winners were companies that identified China’s innovation rise before everyone accepted it. The next winners will be companies that can separate real assets from noisy pipelines.
Big Pharma still controls global commercialization, regulatory experience, pricing strategy and late-stage execution. But China is increasingly supplying the molecules that can fill tomorrow’s pipelines. That changes the balance of power.
For Pfizer, BMS, Lilly and others, China is no longer just a market. It is a source of future blockbusters. For China biotech companies, licensing is no longer a survival strategy. It is a global expansion model. For India, this is a warning that export volume alone will not define future leadership. For investors, the message is simple: the next pharma winner may not be the company with the biggest internal R&D budget. It may be the company that knows where to find the best science before the rest of the market wakes up.
Sources: Reuters, Pfizer, Bristol Myers Squibb, Haisco, Evaluate, PIB. Key figures include USD 137.7B China out-licensing value in 2025, 38 China out-licensing deals announced by mid-February 2026, Pfizer-Innovent’s up to USD 10.5B oncology collaboration, BMS-Hengrui’s up to USD 15.2B deal, Lilly-Haisco’s up to USD 3B collaboration, Evaluate’s USD 300B patent-cliff risk by 2030, and India’s USD 30.47B pharma exports in FY 2024–25.
-
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The China Biotech Pipeline Grab How Big Pharma Started Buying Innovation From China A data-heavy pharma case study on how Pfizer, BMS,…
-
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy A…
-
How GLP-1 Became Pharma’s Most Powerful Growth Story
How GLP-1 Became Pharma’s Most Powerful Growth Story